Third Pole Therapeutics
PrivateLast Round
Convertible Debt
Mar 13, 2025
Total Funding Raised
$123.38M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Third Pole Therapeutics operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Convertible Debt round in March 2025.
Third Pole Therapeutics is a medical device company that develops innovative portable inhalation devices capable of generating nitric oxide on-demand to provide life-saving therapies for various cardiopulmonary conditions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Third Pole Therapeutics Comparables
Compare Third Pole Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nanjing Novlead Biotechnology | 86% | |
| Beyond Air | 83% | |
| International Biomedical, Ltd. | 82% |
For institutional investors. Book with your work email.
Third Pole Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Mar 13, 2025 | ||||
| Series B | Dec 14, 2022 | ||||
| Series B | Feb 3, 2022 | ||||
| Debt | Apr 15, 2021 | ||||
| Series B | Mar 5, 2019 | ||||
Series B | Mar 5, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Third Pole Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Heart, Lung, and Blood Institute | Series B, Grant |
| National Center for Advancing Translational Sciences | Series B |
| Saturn Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 54% MoM, from 1.3K to 2K.
- Jul 26, 2026
Monthly visitors grew 117% MoM, reaching 1.3K.
For institutional investors. Book with your work email.
Third Pole Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Third Pole Therapeutics's valuation, stock price, and market status.
Is Third Pole Therapeutics a public or private company?
Third Pole Therapeutics is a private company.
What is the current stock price of Third Pole Therapeutics?
Third Pole Therapeutics is a private company, so its shares have no public market price. Caplight tracks Third Pole Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Third Pole Therapeutics worth (valuation)?
Valuation information for Third Pole Therapeutics is not publicly available.
Can I buy Third Pole Therapeutics stock?
Third Pole Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Third Pole Therapeutics's last funding round?
Third Pole Therapeutics's most recent funding round was Convertible Debt on March 13, 2025.
Who are the main investors in Third Pole Therapeutics?
Key investors in Third Pole Therapeutics include National Heart, Lung, and Blood Institute, National Center for Advancing Translational Sciences, Saturn Partners.
Will Third Pole Therapeutics IPO soon?
No public IPO plans have been announced for Third Pole Therapeutics.
How can I track Third Pole Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Third Pole Therapeutics's shares on secondary markets.